ALSO NOTED: BioCryst wins fast-track; i3 buys SKM; GNI to merge with Shanghai Genomics; and much more

> BioCryst Pharmaceuticals of Birmingham, AL said that the FDA has given fast-track development status to Fodosine, its experimental drug for relapsed or refractory T-cell leukemia. Fodosine is in Phase IIa and reportedly features strong binding with a target enzyme. Release

> Global contract research organization i3 has acquired SKM Oncology and its related businesses. SKM is a full-service CRO and a leader in the delivery of oncology clinical trials in Germany. Release

> Japan's GNI is merging with China's Shanghai Genomics. Release

> India's Matrix Labs is buying Belgium's Docpharma - a sales and marketing operation - for $263 million. Release

> The FDA has approved Cornerstone BioPharma's pain medication, Balacet 325. Release

> Biotech startup iCeutica says it has closed its first round of venture capital. Release

> The FDA has extended its review of Solvay's sNDA for Aceon. Release

> Sweden's Karo Bio launched a Phase I trial of KB2115 for obesity. Release

> Skyepharma has gained Germany's approval for its drug to treat asthma and COPD. Report

And finally...Researchers say lifestyle changes could help people with a family history of Alzheimer's avoid the disease. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.